iMPACT Trial: Tirofiban versus Different Glycoprotein IIb/ IIIa Inhibitors and Anticoagulation Regimens for PCI: A Network Meta-Analysis - Michael Lipinski, MD, PhD

↳ This is a section part of Moment: CRT 2016 Coronary - The iMPACT Trials: Session I

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$3.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

iMPACT Trial: Tirofiban versus Different Glycoprotein IIb/ IIIa Inhibitors and Anticoagulation Regimens for PCI: A Network Meta-Analysis presented by Michael Lipinski, MD, PhD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$3.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows

Session Name: The iMPACT Trials: Session I

Track: Coronary

Learning Objectives

Update in advances in Complex Coronary Intervention

Other Components in this Moment

Overview

iMPACT Trial: Treatment of Severely Calcified Coronary Lesions with the Coronary Orbital Atherectomy System Micro Crown: Early Results from the COAST Trial - Richard Shlofmitz, MD

iMPACT Trial: Tirofiban versus Different Glycoprotein IIb/ IIIa Inhibitors and Anticoagulation Regimens for PCI: A Network Meta-Analysis - Michael Lipinski, MD, PhD

Live Case Demonstration from Mount Sinai Medical Center - New York, NY